Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze the results of incidence and severity of acute and
chronic GVHD, (see addendum II) and of disease free survival with Alemtuzumab use
(MabCampath®) in haematopoietic transplant of unrelated donor with reduced intensity
conditioning.
Phase:
Phase 2
Details
Lead Sponsor:
CABYC
Collaborator:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea